SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Incyte Corporation NASDAQ:INCY | $24.66B | $120.97 | Undervalued | 13.7 | +13.39% |
IDEAYA Biosciences, Inc. NASDAQ:IDYA | $3.08B | $31.83 | Not rated | -19.5 | -21.42% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -6.05% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | +11.20% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -46.07% |
Crescent Biopharma, Inc. NASDAQ:CBIO | $525.59M | $14.15 | Not rated | -3.3 | -4.62% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -0.20% |
Ascentage Pharma Group International NASDAQ:AAPG | $339.78M | $14.62 | Not rated | -8.9 | -59.33% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +96.43% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +27.92% |
Continue the stock analysis
Jump to another research area for this company.